Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session: Haematological malignancies

617O - Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical results

Date

10 Sep 2022

Session

Proffered Paper session: Haematological malignancies

Topics

Tumour Site

Haematological Malignancies

Presenters

Chunkang Chang

Citation

Annals of Oncology (2022) 33 (suppl_7): S283-S294. 10.1016/annonc/annonc1055

Authors

C. Chang1, Z. Xiao2, Q. Li3, X. Yan4, T. Qin2, H. Tong5, M. Dai6, Y. He7, J. Weng8, J. Li9, S. Gao10, R. Fu11, X. Wei12, X. Ma13, Y. Zhang13, W. Huang13, Q. Wang13, L. Gu13, Y. Meng13, A. Zhu13

Author affiliations

  • 1 Hematology Department, Shanghai Sixth People's Hospital, 200233 - Shanghai/CN
  • 2 Mds Diagnosis And Treatment Center, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, 300020 - Tianjin/CN
  • 3 Hematology Department, Union Hospital affiliated to Tongji Medical, College of Huazhong University of Science and Technology, 430000 - Wuhan/CN
  • 4 Hematology Department, The First Affiliated Hospital of China Medical University, 110001 - Shenyang/CN
  • 5 Hematology Department, the First Affiliated Hospital, Zhejiang University School of Medicine, 310003 - Hangzhou/CN
  • 6 Hematology Department, Nanfang Hospital of Southern Medical University, 510515 - Guangzhou/CN
  • 7 Hematology Department, Zhujiang Hospital of Southern Medical University, 501280 - Guangzhou/CN
  • 8 Hematology Department, Guangdong Provincial People's Hospital, 510000 - Guangzhou/CN
  • 9 Hematology Department, Peking Union Medical College Hospital, 100730 - Beijing/CN
  • 10 Hematology Department, The First Hospital of Jilin University, 130021 - Changchun/CN
  • 11 Hematology Department, Tianjin Medical University General Hospital, 300052 - Tianjin/CN
  • 12 Hematology Department, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, 450008 - Zhengzhou/CN
  • 13 Research And Development, I-Mab Biopharma Co., Ltd. - Headquarter, 201210 - Shanghai/CN
More

Resources

Login to access the resources on OncologyPRO.

Abstract 617O

Background

Lemzoparlimab (TJ011133) is a differentiated CD47 antibody targeting a distinct epitope to enable a unique red blood cell sparing property while retaining strong anti-tumor activity. We report initial data in an ongoing phase 2 trial in HR-MDS (NCT04202003).

Methods

Patients with untreated IPSS-R intermediate or high-risk MDS, received lemzoparlimab at 30 mg/kg IV weekly and AZA at 75 mg/m2 SC on Days 1–7 in a 28-day cycle. Efficacy was assessed by IWG 2006 criteria per investigator.

Results

As of March 31, 2022, 53 patients were enrolled and baseline characteristics includes median age of 65 years (range, 40-80), 74% male, 91% ECOG≤1, 87% MDS with excess blasts according to WHO classification, 59%/9%/32% with good, intermediate, and poor/very poor cytogenetic risk. The patients had aberrant baseline hematologic conditions with decreased median levels of hemoglobin (G3) 71 g/L, platelet (G3) 43×109/L and neutrophil (G2) 1.1×109/L, respectively. Common Grade 3/4 treatment-related AEs (TRAEs) occurring in ≥20% pts included decreased platelet count (60%), decreased neutrophil count (53%), decreased WBC count (53%) and anemia (40%). One patient had Grade 5 pneumonia TRAE. These hematologic changes were commonly observed in MDS patients treated with AZA monotherapy in China (Du 2018). Among the 29 efficacy evaluable patients who received initial treatment ≥ 4 mo, overall response rate (ORR) was 86.2%, with 31% complete response (CR) rate, 10% hematologic improvement (HI) alone, 44.8% marrow CR (5/13 also with HI), and a median treatment duration of 4.6 mo (range, 1.8-10.5). Among the 15 efficacy evaluable patients who received initial treatment ≥ 6 mo, CR rate was 40%. Most CR patients showed reduction in VAF of MDS-related gene mutation and MRD negativity (≤10-4) by flow cytometry. Biomarker analyses suggest potential correlation of certain gene mutation or bone marrow immunophenotyping with clinical response.

Conclusions

Without a priming dose of lemzoparlimab, combination treatment with AZA is well tolerated and showed clinically meaningful efficacy results in newly diagnosed HR-MDS. A randomized phase 3 MDS trial is planned.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

I-Mab biopharma.

Funding

I-Mab biopharma.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.